Expression of activity-dependent neuroprotective protein in the immune system: Possible functions and relevance to multiple sclerosis

NeuroImmunoModulation

Volumn 17, Issue 2, 2010, Pages 120-125

  Braitch, Manjit ^a   Kawabe, Kiyokazu ^a   Nyirenda, Mukanthu ^a   Gilles, Lucie Jean ^a   Robins, R Adrian ^a   Gran, Bruno ^a   Murphy, Sean ^b   Showe, Louise ^c   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Activity dependent neuroprotective protein; Cytokines; Multiple sclerosis; NAP

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN ANTIBODY; CD40 LIGAND; CD69 ANTIGEN; GAMMA INTERFERON; MESSENGER RNA; NAP PEPTIDE; PEPTIDE; PROTEIN ANTIBODY; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROPROTECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE;

ANTIGENS, SURFACE; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; CYTOPROTECTION; DOWN-REGULATION; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MONOCYTES; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; NEUROIMMUNOMODULATION; OLIGOPEPTIDES; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 70449650452     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258695     Document Type: Article

References (18)

1. Zusev M, Gozes I: Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 2004; 123: 33-41.
2. Li H, Mei Y, Wang Y, Xu L: Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006; 26: 430-437.
3. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, Delgado M: Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 2006; 168: 1179-1188.
4. Gozes I: Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther 2007; 114: 146-154.
5. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I: Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001; 276: 708-714.
6. Gozes I, Divinski I: The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J Alzheimers Dis 2004; 6:S37-S41.
7. Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D: NAP, a peptide derived from the activity- dependent neuroprotective protein, modulates macrophage function. Ann NY Acad Sci 2006; 1070: 500-506.
8. Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE: A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann NY Acad Sci 2000; 921: 115-118.
9. Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE: A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann NY Acad Sci 1999; 897: 125-135.
10. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM: The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res 2005; 2: 149-153.
11. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA: Loss of functional suppression by CD4+CFD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979.
12. Kierdorf K, Wang Y, Neumann H: Immunemediated CNS damage. Results Probl Cell Differ 2009.
13. Kosmaczewska A, Bilinska M, Ciszak L, Noga L, Pawlak E, Szteblich A, Podemski R, Frydecka I: Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). J Neuroimmunol 2007; 189: 137-146.
14. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL: Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997; 94: 599-603.
15. Segal BM: The role of natural killer cells in curbing neuroinflammation. J Neuroimmunol 2007; 191: 2-7.
16. Martino G, Grohovaz F, Brambilla E, Codazzi F, Consiglio A, Clementi E, Filippi M, Comi G, Grimaldi LM: Proinflammatory cytokines regulate antigen-independent Tcell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann Neurol 1998; 43: 340-349.
17. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-1102.
18. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H: The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-1189.